東洋美人ホールディングス
TOYO   BIJIN   HOLDINGS
III INVESTMENT

Patient capital, in service of patient science.

Patient capital, in service of patient science.

Toyo Bijin Capital is the Group's strategic investment arm — not a financial portfolio, nor a short-cycle fund. Industrial synergy is our only criterion, and we grow alongside our portfolio companies over horizons that can span twenty years.

Strategic Capital Engine · Strategic Capital EngineThe Group's Strategic Investment ArmEstablished · Tokyo Ginza

Key facts

  • TOYO BIJIN HOLDINGS runs a dual-engine model combining R&D and strategic investment.
  • Toyo Bijin Capital, the group's investment arm, does not raise outside LP capital.
  • Its average holding period is roughly 8.5 years, matching the 7–10-year R&D cycle in beauty.
  • The portfolio spans three sectors: life science, cosmetics, and wellness.
  • Three portfolio companies' technologies have been folded back into the group's R&D pipeline.
III · PHILOSOPHY

We believe — capital, too, is a form of care.

Financial markets keep time by the quarter; we measure it across generations. Short-cycle capital chases the steepness of the return curve; we keep pace with the patient, long-horizon work of the laboratory.

Toyo Bijin Capital does not invest in stories. We invest only in researchers willing to spend ten years validating a single hypothesis. We do not invest in valuation; we invest only in long‑term synergy that can flow back to the Group's core business.

We call this — restrained ambition.

「Short-cycle capital chases the steepness of the curve; long-term capital is rewarded for its patience.」
III · THREE PRINCIPLES

Three uncompromising rules of investment.

01

Only Industrial Synergy

We do not invest in pure financial portfolios. Every commitment must form a verifiable coupling with the Group's dual-engine strategy — upstream raw materials, midstream process, or downstream channels.

02

Only Long‑Termism

Our exit window begins at ten years. The time of portfolio companies need not align with the quarterly reports of capital — it is determined by the maturity of the science.

03

Only Value That Flows Both Ways

Returns on investment must flow back to the Group's core business. The scientific breakthroughs, manufacturing processes, and channels of portfolio companies should ultimately return to Maison Bijin and Bijin Privé as products, materials, or markets.

III · THREE DIMENSIONS

Three investment axes that interlock with the Group's core business.

  1. UPSTREAM
    01

    Biotech Ventures

    Upstream · Biotech Ventures

    An early pipeline of new raw materials, new molecules, and new delivery mechanisms for the Kyoto Life Sciences Institute.

  2. MIDSTREAM
    02

    Process Patents

    Midstream · Process Patents

    Core process assets that improve the yield, stability, and cost structure of the Group's products.

  3. DOWNSTREAM
    03

    Premium Channel Resources

    Downstream · Premium Channels

    Opening, for our brands, the scarce channels of prestige retail, private clubs, and cross-border high-end markets.

III · THE CURRENT PORTFOLIO

A portfolio built to withstand scrutiny.

We do not publish fund size — only synergy results. The figures below are as of Q1 2026.

8
Industrial Synergy Holdings
Portfolio Companies
3
Already Compounding into Product Lines
Already Compounding
12
2027 Target Portfolio Size
Target by FY2027
III · A REPRESENTATIVE CASE

Kyoto Life Sciences Startup · 2018

The fullest echo of dual-engine synergy.

From a single early-stage commitment in 2018 to a serum on the Ginza flagship counter in 2026 — seven years of disciplined patience are how we prove the strategic capital engine is real, not rhetoric.

  1. 2018
    Strategic Commitment

    Investment in a Kyoto-based bio-science startup focused on fibroblast activation.

  2. 2020 — 2024
    The Institute Takes Over

    Based on this raw material, the Kyoto Life Sciences Institute completed the molecular design, formulation harmonization, and multi-stage clinical validation of the 12th-generation revitalizing complex.

  3. 2025
    Flagship Launch

    The Bijin Privé 12th-generation revitalizing serum launched, becoming the Group's most significant single product of the past decade.

  4. 2026
    Global Extension

    Extension to the North American, European, and Southeast Asian markets; sales flow back into the strategic investment fund, and the Group launches a second round of investment in upstream bio-science targets.

「Patient capital gives research the time to mature; in turn, the results of that research renew the capital that made them possible.」
III · READ DEEPER

Five directions.

The investment chapter unfolds across five sections — each stands on its own, yet together they speak to one another.

Note: Both "Portfolio" and "Alliances" in this section refer to industrial synergy companies on the capital dimension — different in nature from the academic "External Collaboration" in the Science section (II-6). Please do not conflate them.

III · THE DUAL-ENGINE ECHO

Capital is only one of the engines.

The other is our laboratory in Kyoto.

Read · The Dual‑Engine Business ModelI—5  →Go to · The Life Sciences EngineII  →